D
Dunad Therapeutics
Tunable covalent chemistry for developing oral degradable medicines
About Dunad Therapeutics
Dunad Therapeutics, founded in 2020 by Professor Patrick Gunning and Dr. Diana Kraskouskaya, is a biopharmaceutical company that develops orally bioavailable, small molecule protein degradation therapies. The company operates from Cambridge, UK, and Cambridge, Massachusetts, focusing on creating medicines for oncology and Central Nervous System (CNS) disorders.
The company's core is its proprietary platform that utilizes tunable, mono-valent small molecules to induce the degradation of disease-causing proteins. This technology directly modifies the target protein, a novel mechanism that is designed to overcome challenges faced by other protein degradation technologies, such as achieving oral bioavailability and CNS accessibility. The platform is target-class agnostic, aiming to address proteins that have been considered 'undruggable'.
Co-founder Patrick Gunning, a Professor of Chemistry at the University of Toronto, has an extensive background in medicinal chemistry, focusing on inhibitors for various protein classes. His research group's work was foundational for Dunad. Co-founder Diana Kraskouskaya holds a PhD in Medicinal Chemistry and has experience in co-founding other biotech companies, bringing expertise in company building and drug discovery program strategy.
Dunad's business model involves both advancing its internal pipeline and engaging in strategic collaborations. A significant milestone was a 2021 partnership with Novartis to develop covalent and protein-degrading drugs for up to four targets. The agreement included a $24 million upfront payment and equity investment, with potential milestone payments up to $1.3 billion plus royalties. Under this collaboration, Dunad is responsible for research and discovery up to lead optimization, while Novartis will handle subsequent development and commercialization. The company's initial financing came from Epidarex Capital, and its investor base has expanded to include Alpha Wave Global, BioGeneration Ventures (BGV), and Wellington Partners.
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- Whittlesford, United Kingdom
- Sector
- Biotech & Life Sciences
News
Open roles
Dunad Therapeutics in the Whittlesford ecosystem
The Dunad Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Epidarex Capital
BioGeneration Ventures
Amblyotech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dunad Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dunad Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

